Show simple item record

dc.contributor.authorVázquez, Carmen
dc.contributor.authorTolón, Rosa M.
dc.contributor.authorMª Teresa, Grande
dc.contributor.authorCaraza, Marina
dc.contributor.authorMoreno, Marta
dc.contributor.authorKoester, Erin C.
dc.contributor.authorVillaescusa, Borja
dc.contributor.authorRuiz Valdepeñas, Lourdes
dc.contributor.authorFernández Sánchez, Francisco Javier
dc.contributor.authorCravatt, Benjamin F.
dc.contributor.authorHillard, Cecilia J.
dc.contributor.authorRomero, Julián 
dc.date.accessioned2019-11-04T12:03:34Z
dc.date.available2019-11-04T12:03:34Z
dc.date.issued2015
dc.identifier.issn0197-4580spa
dc.identifier.urihttp://hdl.handle.net10641/1712
dc.description.abstractThe modulation of endocannabinoid (EC) levels and the activation of cannabinoid receptors are seen as promising therapeutic strategies in a variety of diseases, including Alzheimer’s disease (AD). We aimed to evaluate the effect of the pharmacological and genetic inhibiton of anandamide (AEA)-degrading enzyme in a mouse model of AD (5xFAD). Pharmacological inhibition of the fatty acid amide hydrolase (FAAH) had little impact on the expression of key enzymes and cytokines as well as on the cognitive impairment and plaque deposition and gliosis in 5xFAD mice. CB1 blockade exacerbated inflammation in this transgenic mouse model of AD. The genetic inactivation of FAAH led to increases in the expression of inflammatory cytokines. At the same time, FAAH-null 5xFAD mice exhibited a behavioral improvement in spatial memory that was independent of the level of anxiety and was not CB1-mediated. Finally, mice lacking FAAH showed diminished soluble amyloid levels, neuritic plaques and gliosis. These data reinforce the notion of a role for the endocannabinoid system in neuroinflammation and open new perspectives on the relevance of modulating endocannabinoid levels in the inflammed brain.spa
dc.language.isoengspa
dc.publisherNeurobiology of Agingspa
dc.rightsAtribución-NoComercial-SinDerivadas 3.0 España*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/3.0/es/*
dc.subjectEndocannabinoidspa
dc.subjectAmyloidspa
dc.titleEndocannabinoid regulation of amyloid-induced neuroinflammationspa
dc.typearticlespa
dc.description.versionpre-printspa
dc.rights.accessRightsopenAccessspa
dc.description.extent687 KBspa
dc.identifier.doi10.1016/j.neurobiolaging.2015.08.003spa
dc.relation.publisherversionhttps://www.sciencedirect.com/science/article/abs/pii/S0197458015004145?via%3Dihubspa


Files in this item

FilesSizeFormatView
VAZQUEZ ET AL-REV1 DEF.pdf686.8KbPDFView/Open

This item appears in the following Collection(s)

Show simple item record

Atribución-NoComercial-SinDerivadas 3.0 España
Except where otherwise noted, this item's license is described as Atribución-NoComercial-SinDerivadas 3.0 España